bluuebunny/crossref_metadata_2025_split huggingface dataset:
End of life (EOL) care in head and neck squamous cell carcinoma (HNSCC) compared to other solid tumors (OST) in Washington (WA) State.
Authors: Shih Lauren , Sun Qin , Fedorenko Catherine R. , Futran Neal D. , Barber Brittany , Marchiano Emily , Parvathaneni Upendra , Liao Jay Justin , Rodriguez Cristina P. , Ramsey Scott David , Shankaran Veena 
Published: June 2024

11147 Background: Real world data describing EOL care in HNSCC is limited. We performed a retrospective study evaluating EOL in HNSCC vs OST in a population-based sample of patients in WA. Methods: We used a database linking WA state cancer registry records with claims records from Medicare, Medicaid, and two large commercial insurers. Patients with HNSCC (oral cavity, oropharynx, hypopharynx, or larynx) were compared to OST (any solid tumor diagnosis). Adults with AJCC stage II-IV or SEER stage Regional/Distant who died in 2011-2021 with continuous insurance enrollment 6 months before death were included. We compared proportions of patients with >1 ED visits in the last 30 days of life, ICU admission in the last 30 days of life, chemotherapy in the last 14 days of life, and hospice enrollment at least 3 days prior to death. We performed multivariate regression analysis to determine factors associated with hospice enrollment. Results: 1,389 patients with HNSCC and 41,412 patients with OST were identified. Demographics for HNSCC vs OST included median age 68 vs 73, white race 91.5% vs 90.1%, stage IV 57.5% vs 45.3%. Insurance types for HNSCC vs OST were commercial 8.4% vs 9.8%, Medicaid 16.6% vs 8.8%, Medicare 59.1% vs 65.5%, multiple 15.8% vs 15.9% (p<0.0001). HNSCC patients had lower rates of >1 ED visits compared to OST (14.1% vs 16.4%, p=0.02); there was no significant difference in ICU admission (25.1% vs 24.0%, p=0.3) or chemotherapy receipt (6.3% vs 5.1%, p=0.056). Hospice enrollment was significantly lower in HNSCC patients (49.0% vs 56.4%, p<0.0001). A stratified analysis limited to stage IV patients yielded consistent findings in all categories. HNSCC patients died more at home and less in hospice (20.2% vs 12.7% and 41.5% vs 52.0%, p<0.0001). In a multivariate regression analysis (Table) HNSCC, black race, living with a partner, or living in neighborhoods with higher area deprivation index (ADI) was associated with lower hospice enrollment. Patients with Medicare or multiple insurance types were more likely to enroll in hospice; AJCC stage was not significant. Conclusions: In this population-based sample, compared to OST, a greater proportion of HNSCC patients were insured by Medicaid at EOL and were less likely to enroll in hospice prior to death. The reasons driving these observed disparities in hospice enrollment warrant further study to optimize EOL care among patients with HNSCC. [Table: see text]
Understanding trends of US breast cancer hospitalization, mortality and costs using the National Inpatient Sample database.
Authors: Kumar Arun , Solangi Zeeshan , Agudile Emeka , Elmanaseer Oday , Shah Ghulam , Devi Amirta , Whitaker Kristen Danielle 
Published: June 2024

11162 Background: Studies have shown a rising breast cancer incidence in the US. However, its impact on healthcare utilization is unclear. Our study delves into the previously unexplored territory of hospitalization and cost trends among breast cancer patients, aiming to shed light on resource allocation and potential areas for improvement. Methods: To investigate trends in breast cancer admissions and costs, we queried the National Inpatient Sample database. Patients admitted between January 2011 and December 2019 with following criteria were included in the analysis: female gender, age ≥ 18, and ICD diagnosis code corresponding to unspecified malignant neoplasm of the breast as their primary reason for admission. Our primary outcome was defined as the temporal trends in the number of admissions, discharge rates, length of stay, and cost of hospitalization and mortality rates. Analyses were performed using Stata version 15.1 College station TX: StataCorp LP 2017. Appropriate discharge weights were applied to the dataset during the analyses to account for critical elements of sampling design. A p-value of <0.05 was considered statistically significant. Results: Between 2011 and 2019, hospital admissions for breast cancer as the primary diagnosis declined significantly, from 32,126 to 12,742 (P < 0.001). However, while average length of stay increased slightly from 4.3 to 4.9 days (P < 0.01), hospital charges for breast cancer rose dramatically. Adjusted for inflation, mean charges per patient rose 38.8%, from $50,663.86 in 2011 to $70,334.11 in 2019 (P < 0.001). Despite this surge, the total aggregate cost ("national burden") of hospitalizations with breast cancer as main discharge diagnosis decreased, falling from $1.63 billion in 2011 to $896 million in 2019 (inflation adjusted) (P < 0.001). Discharges for breast cancer peaked in women between 45 and 64, followed by the 65-84 demographic. Compared to the overall decrease in hospitalization rates, the declines in the above age groups were notably steeper with declines of 62% for 45-64 and 48% for 65-84 (p<0.001). Although absolute number of breast cancer deaths decreased from 2011 to 2019, the mortality rate paradoxically increased from 4.3% to 5.8% over the same period (P < 0.001). This seemingly contradictory trend warrants further investigation to better understand contributing factors. Conclusions: While breast cancer diagnoses are on the rise in women, our study reveals a fascinating paradox: significant declines in hospitalization, associated costs, and overall mortality. This encouraging trend likely stems from widespread surveillance mammography with increases in early stage, curable disease diagnosis, and the flourishing landscape of outpatient therapies, including targeted treatments, with more tolerable toxicity profiles allowing for majority of breast cancer care to be completed in the outpatient setting.
Geographic and sociodemographic variations in disease burden, epidemiological trends, and risk factors of early-onset lung cancer: A global analysis.
Authors: Li Wang-Zhong , Gui Xianhua , Liang Hengrui , Wang Wei , Liang Wenhua , He Jianxing 
Published: June 2024

11169 Background: Exploring the emerging trend of early-onset lung cancer (EOLC) burden is pivotal for guiding the implementation of preventive strategies among young adults. We aimed to provide a comprehensive examination of the geographic and sociodemographic variations in the disease burden, along with epidemiological trends and risk factors associated with EOLC over the past three decades. Methods: EOLC refers to lung cancer diagnosed in individuals aged 20-49 years. Utilizing the GBD 2019 data, we estimated the age-standardised incidence, mortality, and disability-adjusted life years (DALYs) rates for EOLC by sex, socio-demographic index (SDI) quintiles, and geographical location for the period from 1990 to 2019. We investigated the relationships between concomitant risk factors and EOLC incidence at national level, and calculated the DALYs attributable to risk factors. The relative contribution of population growth, population ageing, and epidemiological changes to the variations in burden of EOLC over study period was measured using the decomposition analysis. Incidence was forecast to 2040 using the Bayesian age-period-cohort model. Results: A total of 135,704 EOLC cases, equating to a age-standardised incidence rate of 4.0 (95% UI 3.6 to 4.3) per 100,000, were estimated in 2019 worldwide and was the second leading cause of cancer death among young adults, with higher disease burden occurred in males and those from middle and high-middle SDI regions. An overall decreasing trend in burden of EOLC was observed globally; such trends were more pronounced among males and followed a gradient across SDI levels, with the greater decrease observed in high and high-middle SDI regions. Sex, tobacco smoking prevalence, per capita cigarette-equivalent estimates, average age of smoking initiation, ambient ozone pollution, and GDP per capita were independently and significantly associated with EOLC incidence at the population level. Smoking remained the top contributor to burden of EOLC, with the exception of Andean Latin America, North Africa, and the low SDI regions, where ambient particulate matter pollution and household air pollution from solid fuels ranked as the foremost attributable risk factors. Population growth was the primary driver behind the global increase in EOLC cases in low and low-middle SDI regions, while epidemiological changes accounted for the most substantial reduction in EOLC cases across most regions. The global incidental cases of EOLC was projected to increase by 31.1% in 2040, with a more pronounced increase in females and those from high-middle and middle SDI locations. Conclusions: Our findings underscore significant geographic and sociodemographic disparities in the epidemiological burden of EOLC, emphasizing the necessity for policymakers to devise and apply region-specific, evidence-driven preventive strategies.
Treatment trends for metastatic urothelial carcinoma across eight Mexican centers: A global oncology perspective.
Authors: Beas-Lozano Evelyn Lilian , Remolina Bonilla Yuly Andrea , Caballero Rosa , Sobrevilla-Moreno Nora , Perez Perez Perla , Díaz-Alvarado Maria Guadalupe , Zayas-Villanueva Omar Alejandro Alejandro , Martinez Erika , Campos Gomez Saul , Cardoso Aparicio Luis Arturo , Mendoza Oliva Dolores , Bourlon Maria T. 
Published: June 2024

11171 Background: Urothelial carcinoma represents 3% of new cancer cases globally. Metastatic urothelial carcinoma (mUC) poses a notable challenge to healthcare systems, given its treatment complexity and high mortality. These challenges are magnified in resource-constrained settings. We aim to describe treatment trends for mUC across public and private Mexican centers. Methods: Retrospective study across 8 referral centers. Adults with mUC from 01/2001-12/2021 were included. We assessed clinical records, demographics and comorbidities. We recorded subject eligibility for first line platinum therapy, treatment lines received, and access to novel drugs. Descriptive statistics were used for demographics, treatment details and outcomes. Survival analysis was performed, including Kaplan Meier curves and Cox proportional hazards model. Results: We found 342 cases of mUC, 76% were male, with a median age of 67 years. Median follow-up was 8.4 months. Among those that received a first line (n=223, 65%), regimens used were cisplatin-based chemotherapy (n=100, 45%), carboplatin-based chemotherapy (n=87, 39%), gemcitabine (n=5, 2.2%), immunotherapy (n=4, 1.8%) or unspecified (n=27, 12%). Most causes of cisplatin ineligibility were ECOG ≥2 (41%) and glomerular filtration rate <60 ml/min (33%). Of those who received upfront platinum therapy (n=187), 65% received >3 cycles (n=121), 20% received 2 or 3 cycles (n=38) and 15% received 1 cycle (n=28). Progression as best response was found in 47% (n=88). Avelumab maintenance was only used in 14/99 eligible patients (14.1%). The proportion of individuals receiving a second, third or more lines was 24.6%, 8.8% and 3.5%, respectively. The most common second line treatment was chemotherapy (64.4%) followed by immunotherapy (28.6%). Median overall survival (mOS) was 11.8 months. Treatment notably impacted mOS, favoring those who received a first line(16.7 vs. 4.6 months, p<0.0001). Stratified analysis showed worse mOS for those with visceral disease (17.1 vs 10.3 months, p=0.0065) and ECOG ≥2 (17.6 vs 5.8 months, p<0.001).These features correlated with higher mortality, while first line treatment was associated with lower mortality. Conclusions: These data represent the first effort to delineate treatment trends of mUC in Mexico. First line treatment rates were higher than those described worldwide (35-60%1). Further, cisplatin-eligibility was higher compared to reports of high-income countries. Considerable rates of progression to platinum therapy were found, likely due to aggressive disease. This study highlights the limited access to novel treatments, showed by the infrequent use of avelumab maintenance, immunotherapy or targeted agents. [Table: see text]
Outcomes of liver transplant recipients with pretransplant malignancies: Insights from a single institution’s experience.
Authors: Vobugari Nikitha , Heyne Kirk , Connor Ashton , Ajmal Zainub , Adroja Shubham , Gao Yuan , Mathur Sunil , Kodali Sudha , Saharia Ashish , Mobley Constance M , Elaileh Ahmed M , Patel Khush , Ghobrial Rafik Mark 
Published: June 2024

11173 Background: Increasing liver transplantation (LT) utilization has resulted in more and more patients with a history of a non-hepatobiliary malignancy. Rather than deny such patients a lifesaving therapy the benefits must be weighed against risk of tumor recurrence and de novo malignancies (DNM) post-LT, especially with the immunosuppression required. While data has been presented on outcomes of pre transplant malignancies (PTM) in kidney and heart transplants, LT data is lacking. Our aim is to characterize rates of recurrence, DNM, and overall survival (OS) post-LT at a single, high volume American center. Methods: This retrospective study at Houston Methodist Hospital included patients who underwent LT with known history of PTM. Data was extracted from electronic health records, and descriptive statistics performed. Institutional IRB approval is obtained. Results: Between 01/1999- 12/2022, 1617 LTs were performed at our institute. We identified 261 LT recipients with 297 PTM, including 91 non- and 206 hepatobiliary cancers (See Table). Follow-up period ranged from 1 to 23 years. Post-LT malignancies were observed in 66 patients, 25% of the study population. Tumor recurrences accounted for 44 (17%) cases, and DNM were seen in 22 (8%). The DNMs included skin non-melanoma (n=8 cases), head & neck (3), PTLD (2), prostate (2), renal (1), lung (1), CRC (1), pancreatic (1), gynecologic (2), and poorly differentiated (1). The OS rate at 1-, 5-years (excluding those less than 5 years follow-up and unknown), and at time of last follow-up were 86.6%, 60-65% and 70%, respectively. Patients with post-LT malignancies had lower OS compared to those without (46% vs. 77.7%). Conclusions: To our knowledge, this study is the first to assess post-LT outcomes in patients with PTM. This study of LT recipients with PTM demonstrates post-LT malignancy rates of 25%, including 17% with recurrences and 8% with DNM. The latter is within the previously reported range of 3-14% DNM in the general post-LT population and dominated by skin cancers. Post-LT OS is excellent in these recipients and comparable to all LT patients. However, OS is lower in those with post-LT malignancies, implying a possible role for increased cancer surveillance. Limitations include retrospective design and potential chart bias. Future work in this cohort will focus on immunosuppression effects for this high-risk population. [Table: see text]
Long-term cardiovascular outcomes in survivors of 20 adult solid tumors: Large population-based matched cohort study.
Authors: Krishnan Arunkumar , Kadakia Kunal C. , Walsh Declan , Alqahtani Saleh A 
Published: June 2024

11177 Background: The past few decades have seen notable advancements in how cancer is diagnosed and treated, with improvements in cancer survival. Cardiovascular diseases (CVDs) are the major life-limiting comorbidity among cancer survivors. Evidence is scarce on the risks of specific CVDs in survivors of a wide range of solid tumors, hindering informed strategies for prevention and management. Thus, we evaluated a large population-based U.S. electronic health records database. Methods: This large retrospective cohort study was conducted by using the TriNetX dataset between January 2008 and December 2022. All adult patients (>18 years) with a diagnosis of 20 most common solid tumors alive 12 months after diagnosis were matched with controls without a cancer history in a 1:1 ratio with these a priori identified potential confounders: demographics, BMI, nicotine dependence, comorbidities, labs, and medications. The primary outcome was the first incidence of CVD like heart failure (HF), major adverse cardiovascular events (MACE; unstable angina, myocardial infarction, or coronary artery intervention), or venous thromboembolism (VT), and cerebrovascular events (CVE; stroke, transient ischemic attack, cerebral infarction, carotid intervention). Hazard ratios (HR) were calculated to assess the outcomes. Results: 890126 individuals with a solid tumor of interest followed up at least 1 year later were identified and matched to 1787244 controls. The VT risk was higher among survivors of 18 out of 20 specific solid cancer types than controls. HRs ranged from HR 3.68( 95% CI 3.48-3.89) for kidney cancer and HR 1.27 (95% CI 1.21–1.35) in patients after pancreatic cancer. HRs for VT were more prominent without prior CVDs. Higher risks of CVDs were the most common immuno -and chemotherapy. Higher risk of HF was observed in lung (HR 1.46, 95% CI 1.32–1.89), liver (HR 1.22, 95% CI 1.18–1.26), and ovarian (HR 2.01, 95% CI 1.64–2.45) cancers and in patients younger than 55 years. Pericarditis and arrhythmia were common in lung, bile duct, and stomach cancers. A greater risk of arrhythmia was also observed in lung, kidney, and thyroid cancers, whereas CVE was observed in CNS cancers. Conclusions: Survivors of site-specific solid tumors are at a higher medium to long-term risk of one or more CVDs than the general population. Notably, substantial variations in risk were observed across different cancer primary sites. The outcomes underscore the importance of heightened monitoring for CVDs after a cancer diagnosis.
Intra-read analysis of radiologists in the setting of blinded independent central review of oncology studies.
Authors: Elbahnasawi Amir 
Published: June 2024

11179 Background: This study explored the outcome of an analysis completed on the Intra-reader variability of radiologists when assessing the imaging endpoint surrogates of Date of Progression (DOP) and Best Overall Response (BOR) within the context of Blinded Independent Central Review (BICR) in Oncology clinical trials. The analysis encompassed 55,000 test cases derived from 217 clinical trials involving 138 readers. Methods: Data collection and parsing were executed through a Python script, enabling a manual analysis of the results. The analysis posited that Intra-read variability serves as a valuable tool when seeking to exclusively observe the consistency of readers in a specific re-read setting. Results: The data analysis yielded significant insights, revealing that 89.81% of readers demonstrated substantial and above agreement in DOP determinations, while 72.38% achieved the same in BOR determinations. This suggests a higher level of consistency in DOP compared to BOR determination. Notably, 11 DOP and 20 BOR inconsistencies were observed. This prompted further investigation which led to 5 of the 138 readers being flagged based on discrepancies against their own prior or subsequent reads. The kappa values for these 5 readers ranged from 0.33 to 0.59, consistently indicating fair and moderate agreement. Conclusions: This analysis underscored the role of Intra-read variability in identifying inconsistent readers within the landscape of BICR in Oncology clinical trials. The re-read inconsistency is not a universal requirement, and its application is recommended primarily for complex oncology clinical trials or those with indications known to have elevated adjudication metrics. The study emphasized the potential for targeted retraining strategies based on Intra-read analysis outcomes, contributing to the ongoing refinement of reader proficiency. Future directions may involve further exploration of specific retraining strategies or assessing the effectiveness of exclusively using Intra-read variability as a metric for reader performance.
Impact of social determinants of health on health-related quality of life in cancer survivors.
Authors: Peitz Josephine , Adebamowo Sally Nneoma 
Published: June 2024

11183 Background: Social determinants of health (SDoH) encompass the various environmental conditions that influence health, well-being, outcomes, and potential risks. Adverse SDoH can exacerbate health disparities and result in a reduced health-related quality of life (HRQoL). We conducted an investigation into the impact of SDoH on the HRQoL of cancer survivors. Methods: The study population was a nationally representative cohort of individuals aged 20-80 years who took part in the United States National Health and Nutrition Examination Survey (NHANES) 2001 to 2018 cycles. We evaluated HRQoL by measuring the number of physically unhealthy days, mentally unhealthy days, inactive days, as well as assessing social support and emotional well-being. We used logistic regression models to investigate the impact of each SDoH on the HRQoL of cancer survivors. Results: We included 4,780 participants in our analyses, comprising 2,533 women and 2,247 men. The participants mean age was 66 (±14) years at the time of enrollment, and 55 (±17) years at the time of cancer diagnosis. Among the total study population, non-melanoma skin cancer (16%) was the most prevalent cancer type. After adjusting for age, age at cancer diagnosis and gender, people who had the lowest self-reported health were more likely to have completed fewer years of education (OR 0.380 [95% CI: 0.32 - 0.45], p < 0.0001), be unemployed (OR 2.30 [1.91 - 2.77], p < 0.0001), have lower family income (OR 0.36 [0.28 - 0.45], p < 0.0001), be food insecure (OR 3.90 [2.80 - 5.44], p < 0.0001), not have private health insurance (OR 1.68 [1.37 - 2.07], p < 0.0001), and have been hospitalized overnight in the last year (OR 5.23 [3.49 - 7.83], p < 0.001) compared to those with the highest self-reported health. SDoH including employment status, family income, food security status, health insurance type, and overnight hospital patient status, were significantly associated with physical and mental health, and physically active days. Level of education and food security were significantly associated with social support and emotional well-being. Conclusions: Adverse SDoH were associated with the reduced HRQoL of cancer survivors in the United States. These findings underscore the importance of addressing and mitigating these social determinants in order to alleviate health disparities and improve the overall well-being and quality of life for cancer survivors.